神州细胞：2025年营收15.60亿元，净利润由盈转亏

Core Viewpoint - Shenzhou Cell reported a significant decline in revenue and a net loss for the fiscal year 2025, primarily due to healthcare cost control, price reductions of core products, and increased commercialization and R&D investments [1] Financial Performance - Total operating revenue for 2025 was 156,015.30 million yuan, representing a year-on-year decrease of 37.91% [1] - The net profit attributable to the parent company was -55,329.37 million yuan, indicating a shift from profit to loss [1] - Total assets at the end of the reporting period were 383,328.43 million yuan, an increase of 16.73% compared to the beginning of the year [1] - Equity attributable to the parent company's owners was 13,956.18 million yuan, a decrease of 0.95% from the start of the year [1] Factors Influencing Performance - The performance decline was mainly driven by factors such as healthcare cost control measures, price reductions of key products, and increased investments in commercialization and research and development [1]